ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2004 Financial Results on March 3, 2005
SAN DIEGO, Feb 24, 2005 /PRNewswire-FirstCall via COMTEX/ — ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2004 on Thursday, March 3, 2005, after the U.S. financial markets close.
Uli Hacksell, Ph.D., Chief Executive Officer, and Thomas H. Aasen, Vice President and Chief Financial Officer, will host a conference call and webcast on Thursday, March 3, 2005 at 4:30 p.m. Eastern Time to discuss ACADIA’s financial results and provide an update on the company’s business.
The conference call may be accessed by dialing 800-295-3991 for participants from the United States or Canada and 617-614-3924 for international callers (reference participant passcode 39550576). The conference call will also be webcast live on ACADIA’s website at www.acadia-pharm.com, under the investor relations section, and will be archived there until March 17, 2005.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has four drug programs in clinical development as well as a portfolio of preclinical and discovery assets directed at large unmet medical needs, including schizophrenia, Parkinson’s disease, neuropathic pain, and glaucoma. Using its proprietary drug discovery platform, ACADIA has discovered all of the drug candidates in its product pipeline. ACADIA’s corporate headquarters and biology research facilities are located in San Diego, California and its chemistry research facilities are located near Copenhagen, Denmark.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief Financial Officer